You are using a browser that is not supported by this site. The site will not function properly. Please switch to the latest version of a supported browser such as Chrome, Safari, Edge, or Firefox to use this site.

Resources

United Therapeutics is dedicated to providing resources to help support treatment with Remodulin. Below you’ll find important forms for Remodulin, patient resources, and a Facebook page and informative videos to share with your patients.

Remodulin Referral Form: Complete this Referral Form and submit to your preferred Specialty Pharmacy to provide your patients with Remodulin. For assistance filling out this form, download the Example Form or contact a representative.

Download the Remodulin Referral Form Download the Example Referral Form

SPmix Program Enrollment Form: Complete the SPmix Program Enrollment Form and fax to your preferred Specialty Pharmacy to enroll Remodulin patients.

Download the Remodulin SPmix Enrollment Form

Remodulin uses iAssist to make it easier for patients to begin therapy. At no cost to you, this comprehensive platform helps streamline the referral process so your patients can start Remodulin as soon as possible. Our extensive list of e-support tools includes:

Electronic gathering of a patient’s consent, which can be secured wherever they are
Digital capture of a prescriber’s signature to enable rapid prescriptions and form authorizations
Online Medical Benefit Verification, allowing you to get patient coverage information in real time
Specialty Pharmacy Selection, meaning you can send an electronic prescription directly to an in-network pharmacy
An intuitive automated tool for submitting prior authorizations (PAs) for more than 80% of patients, lowering the processing time from days to minutes

Thanks to iAssist, your office can efficiently prescribe Remodulin for patients who need it most in 5 simple steps:

Create your office’s account and contact information.
Add office staff and contact information.
Add office prescriber(s), prescriber’s NPI and signature, and verify prescriber identity via knowledge-based authentication (KBA).
Add new patients.
Search for prescribed therapy, select submission type, and follow the steps in the solution.

ACCESS iASSIST

DAW Requirements Guide: Find out more about your state or territory requirements for prescribing “Dispense as Written.”

Download the DAW Requirements Guide

PAH Risk Assessment Sheets: Learn more about assessing risk for your PAH patients and help your patients improve their prognosis.

Download the PAH Risk Assessment Sheets

Glossary: An easy way for patients to familiarize themselves with some of the common pulmonary arterial hypertension (PAH) terms they may encounter.

Download the PAH Glossary

Patient Brochure: This brochure helps patients understand treatment with Remodulin and the resources available to them through United Therapeutics.

Download the Patient Brochure

United Therapeutics ASSIST

ASSIST, the Access Solutions and Support Team, is a United Therapeutics resource committed to helping eligible patients obtain access to their prescribed therapies. ASSIST can help PAH patients navigate topics such as insurance coverage, available financial assistance, and in-network pharmacies.

Learn More

For a full library of request forms, patient brochures, and other resources, please visit UnitedByPH.com.

REMODULIN SOCIAL COMMUNITY

The Remodulin Facebook page provides a community and offers support to those impacted by PAH. The page includes a range of educational resources and additional information about treatment with Remodulin.

The Remodulin YouTube page offers a series of helpful videos for your patients about PAH and Remodulin, including life hacks, patient perspectives, and more.

YouTube Video Highlights

Other Informative Videos To Share With Your Patients

DAW=dispense as written; SC=subcutaneous.

Professional Experiences With Remodulin

Important Safety Information

Warnings and Precautions

Chronic intravenous (IV) infusions of Remodulin delivered using an external infusion pump with an indwelling central venous catheter are associated with the risk of blood stream infections (BSIs) and sepsis, which may be fatal. Therefore, continuous subcutaneous (SC) infusion is the preferred mode of administration.
Avoid abrupt withdrawal or sudden large reductions in dosage of Remodulin, which may result in worsening of PAH symptoms.
Titrate slowly in patients with hepatic or renal insufficiency, because such patients will likely be exposed to greater systemic concentrations relative to patients with normal hepatic or renal function.
Remodulin is a pulmonary and systemic vasodilator. In patients with low systemic arterial pressure, treatment with Remodulin may produce symptomatic hypotension.
Remodulin inhibits platelet aggregation and increases the risk of bleeding.

Adverse Reactions

In clinical studies of SC Remodulin infusion, the most common adverse events reported were infusion site pain and infusion site reaction (redness, swelling, and rash). These symptoms were sometimes severe and sometimes required treatment with narcotics or discontinuation of Remodulin. The IV infusion of Remodulin with an external infusion pump has been associated with a risk of blood stream infections, arm swelling, paresthesias, hematoma, and pain. Other common adverse events (≥3% more than placebo) seen with either SC or IV Remodulin were headache (27% vs. 23%), diarrhea (25% vs. 16%), nausea (22% vs. 18%), rash (14% vs. 11%), jaw pain (13% vs. 5%), vasodilatation (11% vs. 5%), edema (9% vs. 3%), and hypotension (4% vs. 2%).

Drug Interactions

Remodulin dosage adjustment may be necessary if inhibitors or inducers of CYP2C8 are added or withdrawn.

Specific Populations

In patients with mild or moderate hepatic insufficiency, decrease the initial dose of Remodulin to 0.625 ng/kg/min of ideal body weight, and monitor closely. Remodulin has not been studied in patients with severe hepatic insufficiency.
Safety and effectiveness of Remodulin in pediatric patients have not been established.
It is unknown if geriatric patients respond differently than younger patients. Caution should be used when selecting a dose for geriatric patients.
There are no adequate and well-controlled studies with Remodulin in pregnant women. It is not known whether treprostinil is excreted in human milk or if it affects the breastfed infant or milk production.

Indication

Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%).

In patients with PAH requiring transition from epoprostenol, Remodulin is indicated to diminish the rate of clinical deterioration. Consider the risks and benefits of each drug prior to transition.

REMISIhcpMAY2021

Please see accompanying Full Prescribing Information for Remodulin.

For additional information, visit www.RemodulinPro.com or call Customer Service at 1-877-UNITHER (1-877-864-8437).

Important Safety Information

Warnings and Precautions

Chronic intravenous (IV) infusions of Remodulin delivered using an external infusion pump with an indwelling central venous catheter are associated with the risk of blood stream infections (BSIs) and sepsis, which may be fatal. Therefore, continuous subcutaneous (SC) infusion is the preferred mode of administration.
Avoid abrupt withdrawal or sudden large reductions in dosage of Remodulin, which may result in worsening of PAH symptoms.
Titrate slowly in patients with hepatic or renal insufficiency, because such patients will likely be exposed to greater systemic concentrations relative to patients with normal hepatic or renal function.
Remodulin is a pulmonary and systemic vasodilator. In patients with low systemic arterial pressure, treatment with Remodulin may produce symptomatic hypotension.
Remodulin inhibits platelet aggregation and increases the risk of bleeding.

Adverse Reactions

In clinical studies of SC Remodulin infusion, the most common adverse events reported were infusion site pain and infusion site reaction (redness, swelling, and rash). These symptoms were sometimes severe and sometimes required treatment with narcotics or discontinuation of Remodulin. The IV infusion of Remodulin with an external infusion pump has been associated with a risk of blood stream infections, arm swelling, paresthesias, hematoma, and pain. Other common adverse events (≥3% more than placebo) seen with either SC or IV Remodulin were headache (27% vs. 23%), diarrhea (25% vs. 16%), nausea (22% vs. 18%), rash (14% vs. 11%), jaw pain (13% vs. 5%), vasodilatation (11% vs. 5%), edema (9% vs. 3%), and hypotension (4% vs. 2%).

Drug Interactions

Remodulin dosage adjustment may be necessary if inhibitors or inducers of CYP2C8 are added or withdrawn.

Specific Populations

In patients with mild or moderate hepatic insufficiency, decrease the initial dose of Remodulin to 0.625 ng/kg/min of ideal body weight, and monitor closely. Remodulin has not been studied in patients with severe hepatic insufficiency.
Safety and effectiveness of Remodulin in pediatric patients have not been established.
It is unknown if geriatric patients respond differently than younger patients. Caution should be used when selecting a dose for geriatric patients.
There are no adequate and well-controlled studies with Remodulin in pregnant women. It is not known whether treprostinil is excreted in human milk or if it affects the breastfed infant or milk production.

Indication

In patients with PAH requiring transition from epoprostenol, Remodulin is indicated to diminish the rate of clinical deterioration. Consider the risks and benefits of each drug prior to transition.

REMISIhcpMAY2021

Please see accompanying Full Prescribing Information for Remodulin.

For additional information, visit www.RemodulinPro.com or call Customer Service at 1-877-UNITHER (1-877-864-8437).

Resources

Referral And Enrollment Forms

iASSIST: A SIMPLER WAY TO SUBMIT REFERRALS

Prescriber Resources

Patient Resources And Support

REMODULIN SOCIAL COMMUNITY

YouTube Video Highlights

Other Informative Videos To Share With Your Patients